The Team
Our Leaders
Dr. Nupam Mahajan, PhD
President & CEO
Dr Nupam Mahajan is a Professor of Surgery, Director of Urological Research and an Endowed Professor of Cancer Research at Siteman Cancer Center, Washington University in St. Louis. He has over a decade of experience in developing new classes of anti-cancer drugs and taking the compounds into clinical trials. He has developed the compound (R)-9b which has completed extensive pre-IND studies and filed for IND. The Phase I clinical trial for prostate and breast cancer patients started in early 2025. The data indicates that (R)-9b is the next generation of AR-antagonist with immune modulatory properties. This clinical trial, PHAROS, is a Phase 1, First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer, and will examine its ability to suppress tumor growth and stimulate anti-tumor immune responses.
Mr. Steve Nemeth
Founder Director
Mr Nemeth is a founder director of the company. He has over 2 decades of experience working on various Wall Street companies, including MS Farrell. His experience has been critical for development of TechnoGenesys as a therapeutic company with multiple IPs.
Dr. Gerald Andriole, MD
Chief Medical Officer
Dr Gerald L. Andriole is the global Chief Medical Officer at Prostatype Genomics. He previously was Professor and Director of Urology in the National Capital Region at the Brady Urologic Institute at Johns Hopkins University, and formerly served as the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine. Dr. Andriole has over 40 years of contributions in prostate cancer screening and prevention research as well as BPH. He led the USA's largest randomized prostate cancer screening trial (NIH PLCO trial) and the international REDUCE prostate cancer chemoprevention trial, and has contributed over 450 peer-reviewed publications. He chaired the Prostate Committee of NCI's PLCO Cancer Screening Trial, the Steering Committee of the international REDUCE Chemoprevention Trial, and the Prostate Committee of the SUO Clinical Trials Consortium. He is a member of the American Urological Association, the Academy of Master Surgical Educators of the American College of Surgeons, the American Surgical Association, the American Association of Genitourinary Surgeons, and the Clinical Society of Genitourinary Surgeons, among other societies.
Dr. Kiran Mahajan, PhD
Founder Director
Dr Kiran is an Associate Professor in the Department of Surgery, and at Siteman Cancer Center, Washington University in St. Louis. She has extensive experience in testing inhibitors in various animal models and deciphering the mechanism of action. She has been involved in development of the compound (R)-9b, which is now in clinical trial.
Dr. Mark McLaughlin, PhD
Advisor
Dr McLaughlin is an expert in anticancer drug discovery and development focused on protein-protein interaction inhibitor design, molecularly targeted radiotherapy, and molecularly targeted immunotherapy for the treatment and cure of targeted cancers.
Dr. Keith Flaherty
Advisor
Dr Flaherty brings extensive clinical and translational oncology expertise, supporting TechnoGenesys' strategic development of (R)-9b through clinical trials.
Dr. Rajen Doshi
Scientific Advisor
Dr Doshi contributes scientific and strategic guidance to TechnoGenesys' drug development programs.
.jpg)
Dr. Venky Ramakrishna
Scientific Advisor
Dr Ramakrishna contributes scientific and strategic guidance to TechnoGenesys' drug development programs.